Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis.

Yiu Ming KhorSarah CuddyHendrik J HarmsMarie F KijewskiMi-Ae ParkMatthew RobertsonHyewon HyunMarcelo F Di CarliGiada BianchiHeather LandauAndrew YeeVaishali SanchorawalaFrederick L RubergRonglih LiaoJohn BerkRodney H FalkSharmila Dorbala

Published in: European journal of nuclear medicine and molecular imaging (2019)

[18F]florbetapir PET/CT offers the potential to noninvasively identify pulmonary AL amyloidosis, and its clinical relevance warrants further study.

Keyphrases

pet ct
positron emission tomography
pulmonary hypertension
multiple myeloma
high resolution
risk assessment
human health
climate change